Citigroup Downgrades Bio-Techne to Neutral, Raises Price Target to $73
Benzinga Newsdesk 4 months ago
NewsDowngradesAnalyst RatingsPrice Target
Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and raises the price target from $70 to $73.
Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and raises the price target from $70 to $73.